Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2025 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has...
November 04, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in November 2025 Investor Conferences

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
October 29, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
October 27, 2025 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
October 22, 2025 12:12 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
October 16, 2025 20:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
September 29, 2025 09:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
September 10, 2025 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial...
August 06, 2025 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough...
July 30, 2025 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...